Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0002 USD | -97.01% | +19,900.00% | -83.33% |
Apr. 12 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
Mar. 08 | Final DIP Financing Approved for Humanigen, Inc. | CI |
Financials (USD)
Sales 2021 | 3.6 | Sales 2022 | 2.51 | Capitalization | 14.29M |
---|---|---|---|---|---|
Net income 2021 | -237M | Net income 2022 | -70M | EV / Sales 2021 | 53,517,059 x |
Net cash position 2021 | 45.01M | Net cash position 2022 | 10.16M | EV / Sales 2022 | 1,644,636 x |
P/E ratio 2021 |
-0.92
x | P/E ratio 2022 |
-0.15
x | Employees | 6 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.65% |
1 day | -97.01% | ||
1 month | -33.33% | ||
3 months | +100.00% | ||
6 months | -90.00% | ||
Current year | -83.33% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 16-01-06 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 20-07-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 16-01-06 |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 20-07-05 |
Ronald Barliant
BRD | Director/Board Member | 78 | 16-01-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.0002 | +19,900.00% | 48,522 |
24-04-19 | 0.000001 | 0.00% | 59,800 |
24-04-18 | 0.000001 | -99.97% | 18,442 |
Delayed Quote OTC Markets, April 26, 2024 at 02:34 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-83.33% | 798K | |
-4.66% | 87.53B | |
+1.32% | 40.42B | |
-19.27% | 29.48B | |
+57.86% | 25.43B | |
-17.69% | 11.49B | |
-43.00% | 11.3B | |
-9.14% | 11.1B | |
+5.24% | 8.75B | |
-8.42% | 7.99B |
- Stock Market
- Equities
- HGENQ Stock